The Federal Institute for Drugs and Medical Devices (BfArM) issues information on the realisation of the EU Commission's implementing decision following the European Medicines Agency's (EMA) scientific review of contrast agents containing gadolinium. It is confirmed that the use of some linear gadolinium contrast agents used for MRI imaging is restricted and that the marketing authorisations of other linear gadolinium contrast agents shall be suspended as of 28 February 2018.

Read more:

https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/EN/RV_STP/g-l/gadolinium-kernspin-neu.html

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Gadolinium-containing_contrast_agents/human_referral_prac_000056.jsp&mid=WC0b01ac05805c516f